Dr. Agarwal's Health Care operates a network of 269 eye care facilities in India and 19 in Africa, generating 67% of revenue from surgical services, with 323,000 surgeries in FY26, of which 73% were cataract. The company holds market leadership in Tamil Nadu and Telangana, but the Indian eye care market is fragmented; its scale and brand recognition are uncommon. FY26 EBITDA margin of 28.9% with a PAT margin of 7.9% signals high business quality, far above typical hospital margins, and the 31 bps improvement in EBITDA margin despite heavy greenfield expansion shows structural efficiency.
The persistence of these economics comes from a combination of clinical standardization, in-house training, and patient trust. The company operates its own optometry institute and postgraduate training centers, and has over 360 international publications, which builds a physician pipeline and protocol-driven care. New facilities ramp quickly due to brand equity, as evidenced by FY25 vintage facilities growing 72% in FY26. The Neo hospital management system, built to scale beyond 5,000 branches and already handling 20,000 patients daily, provides an infrastructure advantage that would take competitors years to replicate. Real estate and licensing constraints further raise entry barriers, making the network's geographical density a defensible asset.
The inflection is the FY27 expansion plan: 60 new facilities (40 surgical, 20 clinics) with 30 in each half, distributed 24 in South, 16 in North, 15 in West. Already 11 have launched in early FY27, and 30 letters of intent are signed, ensuring pipeline visibility. Capex outflow is guided at INR 380-400 crores, including a new Chennai CMS facility targeting launch by October 1, 2026. The merger with Dr. Agarwal's Eye Hospital is expected to conclude by Q3 FY27 (by December 2026). By 18-24 months from now, the network will have exceeded 350 facilities, with the FY26 and FY27 cohorts (totaling over 110 new centers) ramping toward breakeven in 15-18 months. Same-store sales growth of 13-14% for mature facilities plus the contribution of new centers should sustain revenue growth at over 20%, with EBITDA margins remaining stable near 28-29% as operating leverage offsets greenfield losses.
Management has a consistent record of meeting commitments. In FY26, they guided 20% revenue growth and 28% EBITDA margin; nine-month results showed 21.2% revenue growth and 28.4% EBITDA margin, and full-year FY26 delivered 21.6% revenue growth and 28.9% EBITDA margin. They committed to 55-60 new facilities, added 52 in FY26 (or 38 in 9M) and finished with 269; they also closed 5 underperforming clinics, showing discipline. Capex guidance for FY26 was ₹310 crores, with ₹275 crores spent by December 2025, and they are now guiding ₹380-400 crores for FY27, reflecting an accelerated plan. The merger process is on track with NCLT meetings scheduled for July 2, 2026. No guidance has been cut; instead, the company has raised its capacity addition ambition and confirmed stable margins.
The quantified earnings path for the next 18-24 months: FY27 revenue should approach INR 2,500 crores from FY26's INR 2,080 crores (assuming 20% growth), with EBITDA around INR 720 crores at a stable 28.5% margin. PAT will be aided by lower finance costs due to ₹195 crores of debt repaid from IPO proceeds. The critical assumption is that new facility losses, which were INR 30 crores for FY26-opened branches, will remain contained even as the number of surgical centers rises. The single most important watchpoint is the breakeven trajectory of the Delhi-NCR and new West region facilities; if they take longer than the guided 15-18 months, margin erosion could mount. The tension between rising greenfield drag and stable overall margin is operational, not structural, because the company's same-store growth and premiumization (high-end cataract at 26.3% of volumes, Femto procedures up 87% YoY) provide the offset. A falsifier would be a meaningful miss on new facility commissioning or a delay in the Chennai CMS facility, which would indicate execution risk in the expansion machine.
companyname: Dr. Agarwal's Health Care Limited ticker: AGARWALEYE sector: Healthcare / Eye Care Services Dr. Agarwal's Health Care Limited is India's largest integrated eye care network, built on a hub-and-spoke model that spans tertiary, secondary, and primary facilities. The company generates revenue from three segments: surgical services (66% of group revenue in Q1 FY27), diagnosis, consultations and other non-surgical treatments (12%), and the sale of optical products and pharmacy items (22...
Read the full report →capex, geographic expansion, order book surge, acquisition inorganic
FY27 facility additions guided at 60 units driven by expansion into new geographies and deeper penetration of existing markets
Guidance upgradedconsistent
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Dr. Agarwal's Health Care Limited and 4,900+ companies.
5-day free pass. No card required.